Category: Advances in MASH
Overview of Metabolic Dysfunction-Associated Steatohepatitis in Children
G&H What is the current prevalence of metabolic dysfunction-associated steatohepatitis in children? RK Overall, approximately 1 in 6 children have a diagnosis that fits within the […]
Current Status of Genetics and Polygenic Risk Scores in Metabolic Dysfunction-Associated Steatohepatitis
G&H What are the main risk alleles and protective variants for metabolic dysfunction-associated steatohepatitis? NC There are a number of risk alleles, of which the most […]
Use of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis
G&H Why was there a need to develop a therapeutic approach for metabolic dysfunction-associated steatohepatitis? SH Between 30% and 40% of individuals in the United States […]
Update on Treatment for Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis
G&H What is the likelihood that a patient with metabolic dysfunction-associated steatohepatitis has cirrhosis? WA The likelihood of cirrhosis depends on which patients with metabolic dysfunction-associated […]
Examining the Nomenclature Change From NAFLD and NASH to MASLD and MASH
G&H Why was the nomenclature for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis changed? MR From a historical perspective, the terms nonalcoholic fatty liver disease (NAFLD) […]